MannKind Corp expected to post earnings of 4 cents a share - Earnings Preview
06/05/2025 14:10
MannKind Corp MNKD.OQ MNKD.O is expected to show a rise in quarterly revenue when it reports results on May 8 for the period ending March 31 2025 The Danbury Connecticut-based company is expected to report a 14.9% increase in revenue to $76.132 million from $66.26 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data. LSEG's mean analyst estimate for MannKind Corp is for earnings of 4 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts had fallen by about 4.0% in the last three months. Wall Street's median 12-month price target for MannKind Corp is $10.00, above its last closing price of $4.96. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | 0.04 | 0.04 | 0.03 | Missed | -16.7 |
| Sep. 30 2024 | 0.03 | 0.03 | 0.02 | Missed | -33.3 |
| Jun. 30 2024 | 0.00 | 0.01 | -0.01 | Missed | -249.9 |
| Mar. 31 2024 | 0.03 | 0.03 | 0.04 | Beat | 53.8 |
| Dec. 31 2023 | 0.00 | 0.00 | 0.00 | Met | -100 |
| Sep. 30 2023 | -0.02 | -0.02 | 0.01 | Beat | 160.6 |
| Jun. 30 2023 | -0.04 | -0.04 | -0.02 | Beat | 47.4 |
| Mar. 31 2023 | -0.05 | -0.05 | -0.04 | Beat | 20.3 |
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children